Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis? PDF Print E-mail
Thursday, 22 December 2011 20:15
Eric Hachulla, MD, PhD; David Launay, MD, PhD; Luc Mouthon, MD, PhD; Olivier Sitbon, MD, PhD; Alice Berezne, MD; Loïc Guillevin, MD; Pierre-Yves Hatron, MD; Ge´rald Simonneau, MD; Pierre Clerson, MD; and Marc Humbert, MD, PhD;

Pulmonary arterial hypertension (PAH) is a frequent complication in patients with systemic sclerosis (SSc) that has a prevalence of 8 to 12%. Within the last 2 decades, pulmonary fibrosis and PAH have become the leading causes of death in SSc patients. The estimated 3-year survival rate among patients with PAH associated with SSc is approximately 50%. The development of PAH in patients with SSc must be differentiated from that of pulmonary hypertension (PH) associated with severe pulmonary fibrosis. The latter may manifest as a significant reduction of lung volume (FVC 60% predicted and/or total lung capacity [TLC] 60%) and a modest elevation in mean pulmonary artery pressure (mPAP) of 35 mm Hg at rest.

Unlike pulmonary fibrosis, PAH is understood to occur late in the natural course of SSc and more frequently in patients with limited cutaneous SSc (lcSSc). This assertion, however, may benefit from reappraisal. Studies have shown that PAH may be similarly prevalent among patients with diffuse cutaneous SSc (dcSSc) as it is among patients with lcSSc. Robust data estimating the typical duration between the diagnosis of SSc and the diagnosis of PAH are lacking. The aim of this study was to analyze this duration and evaluate the potential relevance of “time of occurrence of PAH” in the course of SSc as a prognostic factor.

Download the full research paper from the link provided below.

 
More articles :

» HSCT Benefits In Early Diffuse Cutaneous Systemic Sclerosis

Initial results from an international, investigator-initiated, open label phase 3 trial, presented at EULAR 2012, indicate that haematopoietic stem cell transplantation (HSCT) results in better long-term survival than conventional treatment for...

» Greater Global Cooperation and Collaboration in Scleroderma Research Required

Greater global cooperation and collaboration among Scleroderma researchers and clinicians would be all that is required to fuel a drive toward important discoveries and optimize outcomes for patients with this chronic, progressive, and often...

» Stem Cell Transplant Helps Retired New Jersey Principal

Covered within a recent article, New Jersey resident, Michael George feels “reborn” after having his own implanted in him to treat his in a new . The retired William C. McGinnis School principal, who in April was taken off all medications,...

» Unite Against Scleroderma A Great Success

Our very first Scleroderma Awareness Walk, "Unite Against Scleroderma" was a great success. Sunday May 1st was a dream that became a reality, simply because family and friends of the Foundation also wanted the community of Trinidad and Tobago to be...

» Pregnancy Complicated by Severe Preeclampsia and Thrombocytopenia in a Patient with Scleroderma

Robert D’Angelo, MD, and Robert Miller, DODepartment of Anesthesiology, Bowman Gray School of Medicine, Wake Forest University, Winston-SalemThe combination of pregnancy and scleroderma is exceedingly rare, yet it can present multiple anethestic...

» New Target Indentified In The Battle Against Rheumatoid Arthritis Identified

Researchers have uncovered the mechanism by which a cell signalling pathway contributes to the development of rheumatoid arthritis (RA). The study led by researchers at Hospital for Special Surgery, also provides proof that drugs under development...